| Literature DB >> 33115724 |
X Sophie Zhang1,2,3,4, Caroline Duchaine5,6.
Abstract
Since the beginning of the COVID-19 pandemic, there has been intense debate over SARS-CoV-2's mode of transmission and appropriate personal protective equipment for health care workers in low-risk settings. The objective of this review is to identify and appraise the available evidence (clinical trials and laboratory studies on masks and respirators, epidemiological studies, and air sampling studies), clarify key concepts and necessary conditions for airborne transmission, and shed light on knowledge gaps in the field. We find that, except for aerosol-generating procedures, the overall data in support of airborne transmission-taken in its traditional definition (long-distance and respirable aerosols)-are weak, based predominantly on indirect and experimental rather than clinical or epidemiological evidence. Consequently, we propose a revised and broader definition of "airborne," going beyond the current droplet and aerosol dichotomy and involving short-range inhalable particles, supported by data targeting the nose as the main viral receptor site. This new model better explains clinical observations, especially in the context of close and prolonged contacts between health care workers and patients, and reconciles seemingly contradictory data in the SARS-CoV-2 literature. The model also carries important implications for personal protective equipment and environmental controls, such as ventilation, in health care settings. However, further studies, especially clinical trials, are needed to complete the picture.Entities:
Keywords: COVID-19; SARS-CoV-2; bioaerosols; infection prevention; inhalable aerosols; low-risk settings; personal protective equipment; respiratory protection; ventilation
Mesh:
Substances:
Year: 2020 PMID: 33115724 PMCID: PMC7605309 DOI: 10.1128/CMR.00184-20
Source DB: PubMed Journal: Clin Microbiol Rev ISSN: 0893-8512 Impact factor: 26.132
Overview of studies and their level of evidence from a clinical perspective
| Types of studies | Level of evidence | Clinical limitations |
|---|---|---|
| Trials comparing masks and respirators in health care settings | Moderate | Lack of clinical trials |
| Laboratory studies on masks | Weak | Artificial conditions |
| Epidemiological studies on transmission | Weak to moderate | Observational data |
| SARS-CoV-1 studies | Weak to moderate | Lack of clinical trials |
| Air and no-touch surface sampling | Weak | Variety of methods |
| Laboratory generation of aerosols | Very weak | Artificial conditions |
This hierarchy is based on clinical relevance and outcomes, inspired by GRADE (182).
RCTs comparing masks to respirators during HCWs exposure to respiratory viruses
| Study details | Outcomes | Limitations |
|---|---|---|
| Symptom-based PCR swab:
| Serious baseline imbalances | |
| Symptom-based PCR swab:
| Serious baseline imbalances | |
| Symptom-based PCR swab + serology for all:
| Unknown % high-risk procedures | |
| Symptom-based PCR swab + two random swabs and serology for all:
| Outpatient setting only |
ARI, acute respiratory illness; CRI, clinical respiratory illness; ILI, influenza-like illness; LCI, laboratory-confirmed influenza; LVI, laboratory-confirmed viral respiratory infection.
Primary outcome.
Secondary outcomes.
Major laboratory studies on the filtration efficiency of masks and respirators
| Study details | Design | Findings/conclusions | Strengths (+) and limitations (−) |
|---|---|---|---|
| 4 human volunteers | Both mask types ineffective | (−) Implausible findings: superiority of cotton and uncontaminated inner layer | |
| 7 human volunteers | Surgical mask:
| (−) Implausible findings: uncontaminated inner layers of mask and respirators | |
| 246 human volunteers randomized to mask or no mask | Coronavirus: complete reduction in droplets and aerosols with mask | (+) Similarity to clinical setting (i.e., many infected pts) | |
| Nebulizer-generated aerosols and bag as aerosol chamber | Filtration efficiency | (−) Particle sizes not measured but assumed from manufacturer guide | |
| 2 manikin heads in a chamber, 3 feet apart: | Coughing: mask or N95 on Source superior to mask or unsealed N95 on Receiver | (+) MMAD measured for each setup | |
| 37 human volunteers | Fine particles exhaled contained more viral copies than coarse particles | (+) Similarity to clinical setting (i.e., many infected pts) | |
| Manikin head (receiver) attached to a breathing simulator | Infectious virus detected behind all masks | (+) Viral culture | |
| Nebulizer-generated microbial aerosols | Surgical masks had best filtration efficiency for microbial aerosols and lowered the no. of emitted particles | (+) Fit factor | |
| 2 manikin heads attached to a coughing and a breathing simulator | Loosely fitted respirator no better than loosely fitted mask in blocking aerosols (>50–60%) | (+) Aerosol sizes measured | |
| A manikin head simulating inhalation | >97% filtration for all | (+) MMAD = 0.774 μm | |
| 2 manikin heads in a chamber, 3 feet apart: source (simulated exhalation) and receiver | Mask on source effective | (+) MMAD measured for each setup | |
| 9 human volunteers coughing | Both N95 and surgical equally effective (complete blockage) | (−) Ballistic particles of unknown size, not aerosols |
MMAD, median mass aerodynamic diameter (indicator of aerosol size); pt(s), patient(s).
Positive SARS-CoV-2 air and no-touch surface sampling studies in health care settings
| Study setting | Design | Proportion of positive samples | Strengths (+) and limitations (−) |
|---|---|---|---|
| | 13 pts in isolation units | Air: 12/19 in rooms, 7/12 in hallway, 4/4 on personal sampler | (+) Evaluation of long-range (e.g., hallway) and short-range (e.g., personal air sampler) |
| | 5 hospitals (including GW, ICU, emergency department) | Air: 2/31 confirmed positive in cohort ward and acute admission unit; 14/31 suspected positive | (+) Viral loads measured |
| | 20 hospitalized pts | Air: 3/195 from 3 different pt rooms (particle sizes, <4 μm and >4 μm) | (+) Aerosol sizes and viral loads measured |
| | 5 pts in AIIRs | Air: 2/3 (particle sizes, >4 μm and 1–4 μm) | (+) Aerosol sizes and viral loads measured |
| | Tertiary hospital (severe cases) and make-shift center (mild cases) | Air: 19/33 (particle sizes, 0.25–1.0 μm and >2.5 μm) | (+) Aerosol sizes and viral loads measured |
| | 10 pts in COVID-19 hospital | Air: 1/46 in corridor; 0/2 EBC, 0/2 exhaled air | (+) Detailed description of pt data and environment (including air flows) |
| | 15 ICU pts and 24 GW pts | Air: 14/40 in ICU, 2/16 in GW | (+) Viral loads measured |
| | 3 symptomatic pts in AIIRS | Air: 0/10 | (+) Sample positivity correlated with clinical data and timing of cleaning |
| | Hospital and quarantine hotel | Air: 1/26 in unventilated hotel toilet | (+) Specific data on exhaled breath |
| | 3 pts in a COVID-19 isolation ward | 5 samples total: 100% positive in contaminated areas, 0% in semicontaminated and clean areas | (+) Viral loads measured |
| | 10–30 pts in different areas of a COVID-19 hospital | Air: 2/14 (in 2 ICU wards with 10 severely ill pts each) | (+) Viral loads measured |
| | Hospital AIIR, long-term care isolation wards, nursing home | Air: 1/12 (maskless hospitalized pt) | (+) Inclusion of long-term care facilities |
| | Air sampling: 6 samplers at 3.5 liters/min for 30 min (105 liters) | Air: 6/6 (particle size, <1 μm) | (+) Aerosol sizes and viral loads measured |
| | 2 pts in a designated COVID-19 ward | Air: 4/4 | (+) Water vapor condensation sampling |
AIIR, airborne infection isolation rooms; ICU, intensive care unit; GW, general ward; TCID50, 50% tissue culture infective dose; pt(s), patient(s); Sx, symptom(s); EBC, exhaled breath concentrate; IPC, infection prevention and control.
Negative SARS-CoV-2 air sampling studies in health care settings
| Study settings | Design | Proportion of positive samples | Strengths (+) and limitations (−) |
|---|---|---|---|
| 6 pts in AIIR | Air: 0/6 | (+) Increased proportion of exhaled air sampled under the umbrella | |
| 44 hospitalized pts | Air: 0/10 | (+) Detailed information on environment and interventions | |
| Designated COVID-19 hospital with 800 severe cases (20 in ICU) | Air: 0/135 | (+) Three replicate samples at each location on separate days | |
| Designated COVID-19 hospital | Air: 0/44 | (−) No description of pts |
AIIR, airborne infection isolation rooms; ICU, intensive care unit; pt(s), patient(s); Sx, symptom(s).
FIG 1A broader airborne model involving inhalable aerosols for SARS-CoV-2 transmission in low-risk health care settings. (A) Worst-case scenario: no protection on either the sick patient (source) or the health care worker (exposure), emission of particles of various sizes (droplets and aerosols) during natural respiratory activity (breathing, talking, and coughing), entry of infectious inhalable aerosols, and impaction in the nose where viral receptors are abundant and infectivity is greatest. (B) Best-case scenario and NIOSH hierarchy of controls: source control (mask-wearing by the sick patient), engineering control (optimal ventilation), and exposure control (droplet-contact PPE worn by the health care worker) to prevent short-range droplet and inhalable aerosol transmission.